Cardiovascular Safety of Denosumab Across Multiple Indications

J Bone Miner Res. 2021 Mar;36(3):617-618. doi: 10.1002/jbmr.4189. Epub 2020 Oct 23.

Authors

Long Shao¹, Xiang-Dong Wu², Wei Huang³

Affiliations

¹ Department of Orthopaedic Surgery, Ningbo No.6 Hospital, Ningbo, China.
² Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
³ Department of Orthopaedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

PMID: 33095450
DOI: 10.1002/jbmr.4189

No abstract available

Publication types

Letter
Comment

MeSH terms

Bone Density Conservation Agents*
Denosumab* / adverse effects
Humans
Risk Factors

Substances

Bone Density Conservation Agents
Denosumab